EngiChem Life Sciences (CEO Ki-Young Son) announced on the 26th that it has acquired a patent for a novel immunomodulatory substance targeting inflammatory immune diseases, 'Immunomodulatory compound based on glycerol derivative (Chemical Formula 3)' from the United States Patent and Trademark Office (USPTO).
The new immunomodulatory substance recently patented by EngiChem Life Sciences is a next-generation new drug candidate that is effective in treating various immune diseases by selectively controlling the overexpression of major inflammatory cytokines such as IL-4, IL-6, and CXCL8 (IL-8).
The substance is structurally stable and designed based on biological components, so it has low toxicity and high biocompatibility, and can be developed into an acute inflammation treatment agent and a long-acting immunomodulator.
In particular, if developed as an indication for immune imbalance disease, it can be applied to autoimmune diseases such as rheumatoid arthritis, acute and chronic inflammatory diseases such as pneumonia and chronic obstructive pulmonary disease (COPD), respiratory infections, allergic diseases such as asthma and atopy, and anticancer immunotherapy.
With this US patent registration, EngiChem Lifesciences has secured the rights to its 'glycerol derivative-based immunomodulatory compound' in Korea (KR), the United States (US), Japan (JP), China (CN), and India (IN).
An official from Engichem Lifesciences said, “This compound has fewer side effects than existing immunosuppressants due to its selective mechanism of action, and it is expected to have high clinical accessibility and economic feasibility as it can be developed into various formulations other than oral administration.” The official continued, “This patent is the second novel immunomodulatory agent patent following the ‘novel 1,2-diacylglycerol immunomodulatory agent’ registered in the U.S. in February. It is a strategic asset for building a differentiated new drug platform in the anti-inflammatory and immunomodulatory treatment market, and we plan to increase the possibility of technology commercialization and licensing out.
- See more related articles
You must be logged in to post a comment.